BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24456271)

  • 1. Metallothioneins and synthetic metal chelators as potential therapeutic agents for removal of aberrant metal ions from metal-Aβ species.
    Xia N; Liu L
    Mini Rev Med Chem; 2014; 14(3):271-81. PubMed ID: 24456271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The redox chemistry of the Alzheimer's disease amyloid beta peptide.
    Smith DG; Cappai R; Barnham KJ
    Biochim Biophys Acta; 2007 Aug; 1768(8):1976-90. PubMed ID: 17433250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-beta metal interaction and metal chelation.
    Cuajungco MP; Frederickson CJ; Bush AI
    Subcell Biochem; 2005; 38():235-54. PubMed ID: 15709482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal Ions in Alzheimer's Disease: A Key Role or Not?
    Liu Y; Nguyen M; Robert A; Meunier B
    Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metal ions and intrinsically disordered proteins and peptides: from Cu/Zn amyloid-β to general principles.
    Faller P; Hureau C; La Penna G
    Acc Chem Res; 2014 Aug; 47(8):2252-9. PubMed ID: 24871565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators.
    Chen LL; Fan YG; Zhao LX; Zhang Q; Wang ZY
    Bioorg Chem; 2023 Feb; 131():106301. PubMed ID: 36455485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation.
    Choi JS; Braymer JJ; Park SK; Mustafa S; Chae J; Lim MH
    Metallomics; 2011 Mar; 3(3):284-91. PubMed ID: 21210061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.
    Savelieff MG; DeToma AS; Derrick JS; Lim MH
    Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metal-dependent interactions of metallothionein-3 β-domain with amyloid-β peptide and related physiological implications.
    Jiang Z; Shen B; Xiang J
    J Inorg Biochem; 2019 Jul; 196():110693. PubMed ID: 31005822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of chelating compounds on Cu
    Mazur T; Malik M; Bieńko DC
    J Inorg Biochem; 2024 Aug; 257():112601. PubMed ID: 38744143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
    Mancino AM; Hindo SS; Kochi A; Lim MH
    Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper-mediated β-amyloid toxicity and its chelation therapy in Alzheimer's disease.
    Singh SK; Balendra V; Obaid AA; Esposto J; Tikhonova MA; Gautam NK; Poeggeler B
    Metallomics; 2022 Jun; 14(6):. PubMed ID: 35333348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox-active metals, oxidative stress, and Alzheimer's disease pathology.
    Huang X; Moir RD; Tanzi RE; Bush AI; Rogers JT
    Ann N Y Acad Sci; 2004 Mar; 1012():153-63. PubMed ID: 15105262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the reactivity of flavonoid compounds with metal-associated amyloid-β species.
    He X; Park HM; Hyung SJ; DeToma AS; Kim C; Ruotolo BT; Lim MH
    Dalton Trans; 2012 Jun; 41(21):6558-66. PubMed ID: 22437427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.
    Summers KL; Roseman G; Schilling KM; Dolgova NV; Pushie MJ; Sokaras D; Kroll T; Harris HH; Millhauser GL; Pickering IJ; George GN
    Inorg Chem; 2022 Sep; 61(37):14626-14640. PubMed ID: 36073854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyphenols as Potential Metal Chelation Compounds Against Alzheimer's Disease.
    Lakey-Beitia J; Burillo AM; La Penna G; Hegde ML; Rao KS
    J Alzheimers Dis; 2021; 82(s1):S335-S357. PubMed ID: 32568200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer's Disease.
    Chaudhari V; Bagwe-Parab S; Buttar HS; Gupta S; Vora A; Kaur G
    Neurotox Res; 2023 Jun; 41(3):270-287. PubMed ID: 36705861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives.
    Fasae KD; Abolaji AO; Faloye TR; Odunsi AY; Oyetayo BO; Enya JI; Rotimi JA; Akinyemi RO; Whitworth AJ; Aschner M
    J Trace Elem Med Biol; 2021 Sep; 67():126779. PubMed ID: 34034029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer's Disease.
    Kim N; Lee HJ
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.